Clinical Trial Update: Phase 0/2 PD-Trigger Study of BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors [EARLY_Phase 1]

View source ↗

Summary

An early-phase Phase 0/2 trial evaluating BGB-58067 in newly diagnosed glioblastoma with MTAP deletion; the study is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• BGB-58067

Snippet

Sponsor: Nader Sanai | Conditions: Glioblastoma (GBM) | EARLY_Phase 1 | Status: NOT_YET_RECRUITING